上腺受体的遗传变异
Andrea Ahles1, Stefan Engelhardt2,3
1Institute of Pharmacology and Toxicology, Technical University of Munich (TUM), Munich, Germany.
Handbook of experimental pharmacology
|August 14, 2023
概括
上腺受体的遗传变异会影响它们的功能. 全基因组关联研究 (GWAS) 突出了两个关键编码变体 (β1-上腺受体p.Arg389Gly和β2-上腺受体p.Thr164Ile) 和许多非编码变体.
科学领域:
- 药物基因组学 药物基因组学
- 分子遗传学 分子遗传学
- 心血管研究研究心血管研究
背景情况:
- 上腺受体 (ARs) 是G蛋白合受体,对生理调节至关重要.
- 在AR基因内的遗传变异可以改变受体功能和信号通路.
- 以前的研究集中在AR变体的体外和候选基因研究上.
研究的目的:
- 通过全基因组协会研究 (GWAS) 识别的经过验证的编码性上受体变异的当前知识的总结.
- 为了提供一个概述的新发现的非编码变体附近的上腺受体基因位置.
- 突出特定上腺受体遗传变异的临床意义.
主要方法:
- 审查体外研究和候选基因关联研究.
- 来自全基因组协会研究 (GWAS) 的大型队列的分析.
- 在腺受体基因中识别和描述编码和非编码遗传变异.
主要成果:
- 两个编码上腺受体变体,β1-AR p.Arg389Gly和β2-AR p.Thr164Ile,一直被验证为GWAS的显著遗传风险因素.
- 确定了56个与上腺受体基因位点相邻的非编码变异,其功能作用基本上是未知的.
- 在确定上腺受体中临床相关的遗传变异方面,GWAS已经发挥了重要作用.
结论:
- 在β1-和β2-腺受体中,特定的编码变异与临床特征密切相关.
- 许多非编码上腺受体变体的功能影响需要进一步研究.
- 上腺受体的遗传变异是个性化医学和理解疾病风险的重要目标.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Adrenergic Receptors (Adrenoceptors): Classification
2.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
922
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
922
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
888
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
888
Adrenergic Agonists: Direct-Acting Agents
1.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.6K


